Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant

• Published in: Nature Portfolio
• Main Authors: Uraki, Ryuta, Kiso, Maki, Imai, Masaki, Yamayoshi, Seiya, Ito, Mutsumi, Ujie, Michiko, Furusawa, Yuri, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Kawaoka, Yoshihiro
• Format: Web Resource
• Language: English; Japanese
• Published: Durham Research Square 19.01.2022
• Subjects: Severe acute respiratory syndrome coronavirus 2

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. A new SARS-CoV-2 variant, designated Omicron, first identified in South Africa and possess many spike protein mutations. Here, we assessed th...